| Early-onset MG (EOMG) | Peak incidence in the 2nd-3rd decades, female predominance (3):1), strongly associated with thymic hyperplasia and anti-AChR antibodies |
| Late-onset MG (LOMG) | Peak incidence after age 50, slight male predominance, associated with thymic atrophy and anti-AChR antibodies, increasingly recognized as the most common form due to aging populations |
| Fluctuating weakness | Weakness worsens with activity and improves with rest |
| Fatigability | Progressive decline in muscle force during sustained or repetitive use |
| Diurnal variation | Symptoms typically worsen toward the end of the day |
| Databases | OMIMOrphanetClinicalTrialsPubMed |